Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03932786 · ClinicalTrials.gov registry record
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
A clinical trial of Cancer Survivor and Retinoblastoma, sponsored by Vanderbilt-Ingram Cancer Center.
- Recruiting
- Registry status
- 900
- Enrollment target
- 11
- Study locations
NCT03932786 is a study of Cancer Survivor and Retinoblastoma that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 900 participants, above the 230-participant average among 25 other Cancer Survivor trials with a reported enrollment target (291% higher). The trial reports 11 study locations across 9 states.
The verdict
NCT03932786, a study of Cancer Survivor and Retinoblastoma, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.
- RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 11
- Study locations
Study Summary
This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Biospecimen collection
- OTHER Questionnaire administration
- OTHER Quality of life assessment
- OTHER Vision assessment
Study Locations (11)
Illinois
- Lurie Children's Hospital - Chicago
- University of Illinois, Chicago - Chicago
Texas
- MD Anderson Cancer Center - Houston
- Texas Childeren's Hospital - Houston
Minnesota
- University of Minnesoa - Minneapolis
Missouri
- Washington School of Medicine at St. Louis - St Louis
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Wisconsin
- Children's Hospital of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2019-01-24 |
| Est. Completion | 2031-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03932786
The ClinicalTrials.gov registry entry for NCT03932786 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 230-participant average among 25 other Cancer Survivor trials with a reported enrollment target (291% higher). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cancer Survivor appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03932786 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Illinois, Texas, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03932786 about?
NCT03932786 is a clinical study titled "Studying Health Outcomes After Treatment in Patients With Retinoblastoma". This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, ident...
What is the current status of trial NCT03932786?
This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2019-01-24. Estimated completion is 2031-01.
What conditions does trial NCT03932786 study?
This clinical trial studies the following conditions: Cancer Survivor, Retinoblastoma, Unilateral Retinoblastoma, Intraocular Retinoblastoma, Biological Sibling.
What interventions are being tested in trial NCT03932786?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Biospecimen collection (PROCEDURE), Questionnaire administration (OTHER), Quality of life assessment (OTHER), Vision assessment (OTHER).
Who is sponsoring clinical trial NCT03932786?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03932786 being conducted?
This trial has 11 study locations across Illinois, Minnesota, Missouri, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer Survivor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Leading Healthy Eating and Activity Promotion Program
RECRUITING · NA
-
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
RECRUITING · NA
-
An Acupuncture Study for Cancer Survivors With Joint Pain
RECRUITING · NA
-
Text -Based Depression Screening Among Cancer Survivors
RECRUITING · NA
-
Making Healthy Habits Stick
RECRUITING · NA
-
Better Options for Chronic Cancer Pain
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.